Beyond Air Inc. Common Stock (XAIR)
Stock · NASDAQ · Health Care
$2.16as of 10/16/2026
Price chart
XAIR Signal Track Record
How signals performed across all stocks →What XAIR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 29 | -12.9% | 34% | September 28, 2026 |
| Bollinger Band Breakout | 17 | -21.9% | 18% | August 13, 2026 |
| Volume Spike | 9 | -31.9% | 0% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -8.4% | 33% | February 3, 2023 |
| Any 20-session window (baseline) | -11.6% | 29% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XAIR
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospi…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 54
- Website
- www.beyondair.net/
Fundamentals
- 1-day range
- $2.2$2.34
- Market cap
- $4.93M
- P/E (trailing)
- —
- P/E (forward)
- -1.36
- EPS (trailing)
- $-68.59
- Dividend yield
- —
- Beta
- 0.30
- Avg. volume
- 223.3K
- Dividend pay date
- January 10, 2017
How Beyond Air Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Jun 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Beyond Air Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XAIRBeyond Air Inc. Common Stock$2.16▼ 2.26%Market cap $4.93MP/E —$2.31$55.6
- INBSIntelligent Bio Solutions Inc. Common Stock$1.5▲ 4.17%Market cap $4.76MP/E —$1.35$24.9
- VVOSVivos Therapeutics Inc. Common Stock$0.131▼ 8.39%Market cap $4.47MP/E —$0.1276$3.28
- GCTKGlucoTrack Inc. Common Stock$0.725▼ 12.86%Market cap $4.25MP/E 0.07$1.77$136.29
- SNOASonoma Pharmaceuticals Inc. Common Stock$1.12▼ 2.61%Market cap $5.99MP/E —$0.8501$4.25
- NXGLNexGel Inc Common Stock$5.59▲ 7.92%Market cap $3.13MP/E —$3$57
- NVNOenVVeno Medical Corporation Common Stock$7.47▼ 5.74%Market cap $6.93MP/E —$7.01$30.8
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XAIR Beyond Air Inc. Common Stock | $4.93M | — | $2.16 | ▼ 2.26% | $2.31$55.6 |
| INBS Intelligent Bio Solutions Inc. Common Stock | $4.76M | — | $1.5 | ▲ 4.17% | $1.35$24.9 |
| VVOS Vivos Therapeutics Inc. Common Stock | $4.47M | — | $0.131 | ▼ 8.39% | $0.1276$3.28 |
| GCTK GlucoTrack Inc. Common Stock | $4.25M | 0.07 | $0.725 | ▼ 12.86% | $1.77$136.29 |
| SNOA Sonoma Pharmaceuticals Inc. Common Stock | $5.99M | — | $1.12 | ▼ 2.61% | $0.8501$4.25 |
| NXGL NexGel Inc Common Stock | $3.13M | — | $5.59 | ▲ 7.92% | $3$57 |
| NVNO enVVeno Medical Corporation Common Stock | $6.93M | — | $7.47 | ▼ 5.74% | $7.01$30.8 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026Yahoo · 10/8/2026
- Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $16.715M EstBenzinga · 10/8/2026
- Beyond Air Reports Q2 Preliminary Revenue Of ~$2.3M, Reiterates FY26 Revenue Range $16M - $18MBenzinga · 10/8/2026
- Beyond Air New US Patent App #20260284331 Published Today For "METHODS EMPLOYING GASEOUS NITRIC OXIDE FOR INHIBITING TUMOR GROWTH".Benzinga · 9/24/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 9/21/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/11/2026
Insider Activity
Insider Actions →- Lin Yi-Chien · October 1, 2026 · Buy15.4K @ $2.8
- Lin Yi-Chien · September 30, 2026 · Buy2.0K @ $2.71
- Lin Yi-Chien · September 29, 2026 · Buy3.0K @ $2.69
- Robert Scott Goodman · July 29, 2026 · Buy34.7K @ $5.76
- Daniel J. Moorhead · July 29, 2026 · Buy4.3K @ $5.76
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Beyond Air Affirms FY2027 Sales Guidance at $16‑18M
Beyond Air Inc. (XAIR) confirmed its FY2027 sales guidance at $16‑18 million, matching the $16.715 million estimate from analysts. The company also reported preliminary Q2 revenue of about $2.3 million and reiterated the same FY2026 revenue range of $16‑18 million. These updates suggest the firm is on track to meet its projected sales targets for the next few years.
Beyond Air Affirms FY2027 Sales Guidance at $16‑18M. Beyond Air Inc. (XAIR) confirmed its FY2027 sales guidance at $16‑18 million, matching the $16.715 million estimate from analysts. The company also reported preliminary Q2 revenue of about $2.3 million and reiterated the same FY2026 revenue range of $16‑18 million. These updates suggest the firm is on track to meet its projected sales targets for the next few years.